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Clinical PerspectiveWhat Is New?The number of cases is greater than those in any previous study on amlodipine use in early pregnancy.What Are the Clinical Implications?The incidence of morphologic abnormalities in the offspring of hypertensive mothers treated with amlodipine in early pregnancy was not higher than in mothers treated with or without other antihypertensives.

Introduction {#jah34232-sec-0008}
============

Pregnancies with chronic hypertension have become increasingly common, partly because of the upward shift of pregnancy ages as well as increasing rates of obesity. Chronic hypertension during pregnancy is a risk factor for various adverse outcomes,[1](#jah34232-bib-0001){ref-type="ref"}, [2](#jah34232-bib-0002){ref-type="ref"} including perinatal complications such as superimposed preeclampsia, premature birth, and low birth weight.

Amlodipine, a calcium channel blocker, is long‐acting and causes relatively few adverse drug reactions associated with vasodilation. Because of these advantages, amlodipine is frequently used for the treatment of hypertension, except for pregnant women. A few studies reported that calcium channel blockers as a group may not pose a significant teratogenic risk even in early pregnancy,[3](#jah34232-bib-0003){ref-type="ref"}, [4](#jah34232-bib-0004){ref-type="ref"}, [5](#jah34232-bib-0005){ref-type="ref"} although information on specific calcium channel blockers is limited.

It was recently reported that hypertension itself may be teratogenic.[6](#jah34232-bib-0006){ref-type="ref"}, [7](#jah34232-bib-0007){ref-type="ref"} In this study, therefore, we compared the pregnancy outcomes of 48 women with amlodipine exposure during the first trimester with those of hypertensive women who received nonamlodipine antihypertensives, as well as those who did not receive any antihypertensive drugs.

Methods {#jah34232-sec-0009}
=======

The authors declare that all supporting data are available within the article and its online supplementary files.

Study Subject {#jah34232-sec-0010}
-------------

In this retrospective study, we examined birth outcomes of pregnant women with chronic hypertension whose deliveries resulted in live births from April 2008 to July 2016 at the National Center for Child Health and Development (NCCHD, Tokyo), Osaka Women\'s and Children\'s Hospital (OWCH, Osaka), and National Cerebral and Cardiovascular Center (NCCC, Osaka). We extracted the data of singletons whose mothers' electronic health records were coded "Hypertension" during pregnancy and of those with "Chronic hypertension" documented in the delivery records. We then excluded those who did not meet the criteria for chronic hypertension[8](#jah34232-bib-0008){ref-type="ref"} and the remainder were included in the final analyses.

Ethics Committee Approval {#jah34232-sec-0011}
-------------------------

This study has been approved by the research ethics boards of these hospitals (NCCHD: 1243, OWCH: 1010, NCCC: M29‐073). The requirement for informed consent was waived. All personal identifying data were removed from the study database so that the individuals could not be identified.

Use of Antihypertensives {#jah34232-sec-0012}
------------------------

The first trimester was defined in this study as the period from estimated conception to 11 weeks and 6 days' gestation. We classified women and neonates exposed to amlodipine in the first trimester into the amlodipine group (Group A), those exposed to antihypertensives other than amlodipine (including other calcium channel blockers) into the other antihypertensive group (Group O), and those not exposed to antihypertensives into the no‐antihypertensive group (Group N).

Clinical Diagnosis {#jah34232-sec-0013}
------------------

We confirmed the diagnosis of hypertension in pregnancy, according to the International Society for the Study of Hypertension in Pregnancy Classification, Diagnosis, and Management Recommendations for International Practice.[8](#jah34232-bib-0008){ref-type="ref"} In this study, therefore, hypertension in pregnancy was defined as "chronic hypertension" if the patient was diagnosed with hypertension before pregnancy, or if hypertension was noted before 20 weeks' gestation. Hypertension was defined as a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg. These measurements were made on at least 2 different occasions. Abnormal proteinuria in pregnancy was defined as the excretion of ≥300 mg of protein in 24 hours or a protein/creatinine ratio of ≥0.30 g/g·Cr. Superimposed preeclampsia was diagnosed if a woman with chronic hypertension developed new‐onset proteinuria in the setting of a rise in blood pressure or a sudden increase in pre‐existing proteinuria.

Data Analysis Framework {#jah34232-sec-0014}
-----------------------

### Primary outcome {#jah34232-sec-0015}

In accordance with the European Surveillance of Congenital Anomalies Guide 1.4 and the Reference Documents[9](#jah34232-bib-0009){ref-type="ref"} developed by European Surveillance of Congenital Anomalies, neonates who exhibited "major anomalies" were considered to have morphologic abnormalities ([Table S1](#jah34232-sup-0001){ref-type="supplementary-material"}).

Study Participant Characteristics {#jah34232-sec-0016}
---------------------------------

Clinical information, such as birth date, underlying disease, past medical history, previous pregnancy complications, family history, as well as information on the course of the index pregnancy and the newborn, were obtained from electronic medical records.

Statistical Analysis {#jah34232-sec-0017}
--------------------

A 95% CI was calculated for the incidence of malformations. *P*\<0.05 was considered statistically significant. The χ^2^ test was used for analyzing primary outcome and discrete variables. Mean values of continuous variables were compared by 1‐way ANOVA. As a subgroup analysis, we repeated the comparison among the 3 groups after excluding 10 women with diabetes mellitus, which is a known risk factor for adverse pregnancy outcomes including congenital anomalies. All analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, NC).

Results {#jah34232-sec-0018}
=======

There were 25 485 live births delivered in this period. Among them, there were 1624 singletons with "Hypertension" documented in their mothers' electronic medical records or "Chronic hypertension" in the delivery records. We excluded preeclampsia and gestational hypertension (n=457), postpartum hypertension (n=683), white coat hypertension, and those who did not meet criteria of hypertension (n=244). We also excluded a case of pulmonary hypertension (n=1) and those without data on blood pressure before 20 weeks' gestations (n=8). A total of 231 Japanese women met the definition of chronic hypertension, and they were included in the final analyses (Figure [1](#jah34232-fig-0001){ref-type="fig"}).

![Flow chart representing the recruiting process of study subjects. There were 25 485 live births delivered in this period. Among them, there were 1624 singletons with "Hypertension" documented in their mothers' electronic medical records or "Chronic hypertension" in the delivery records. After excluding those who did not meet criteria of chronic hypertension, a total of 231 neonates were included in the final analyses.](JAH3-8-e012093-g001){#jah34232-fig-0001}

Forty‐eight neonates were classified into Group A, 54 neonates into Group O, and 129 neonates into Group N. No clear difference in patient background characteristics was observed between groups except that Group A showed a high proportion of women with thyroid disease as the underlying disease, a history of hypertensive disorders of pregnancy and those with a history of fetal growth restriction and that Group O showed a higher age at delivery than Group N (Table [1](#jah34232-tbl-0001){ref-type="table"}).

###### 

Maternal Baseline Characteristics

                                                Amlodipine (n=48)   Other Antihypertensives (n=54)   No Antihypertensives (n=129)   *P* Value
  --------------------------------------------- ------------------- -------------------------------- ------------------------------ -----------
  Age at delivery (y)---mean (SD)               37.5 (4.04)         37.9 (5.04)                      36.3 (4.27)                    0.047
  Height, cm---mean (SD)                        158.3 (4.62)        159.0 (4.64)                     159.0 (5.98)                   0.727
  Prepregnancy body weight, kg---mean (SD)      62.2 (13.03)        66.4 (14.92)                     67.9 (17.10)                   0.107
  Prepregnancy BMI, kg/m^2^---mean (SD)         24.8 (5.02)         26.4 (6.34)                      26.8 (6.42)                    0.153
  Nulliparous, N (%)                            20 (41.7)           26 (48.1)                        70 (54.3)                      0.310
  Underlying disease                                                                                                                
  Diabetes mellitus, N (%)                      3 (6.3)             1 (1.9)                          6 (4.7)                        0.533
  Thyroid disease, N (%)                        7 (14.6)            4 (7.4)                          5 (3.9)                        0.044
  Kidney disease, N (%)                         3 (6.3)             0 (0.0)                          4 (3.1)                        0.184
  Collagen disease, N (%)                       4 (8.3)             2 (3.7)                          2 (1.6)                        0.090
  Congenital heart disease, N (%)               0 (0.0)             0 (0.0)                          1 (0.8)                        0.672
  Previous pregnancy complications                                                                                                  
  Hypertensive disorders of pregnancy, N (%)    19 (39.6)           10 (18.5)                        28 (21.7)                      0.024
  Fetal growth restriction, N (%)               10 (20.8)           5 (9.3)                          7 (5.4)                        0.008
  Smoking during pregnancy, N (%)               0 (0.0)             3 (5.6)                          5 (3.9)                        0.287
  Alcohol consumption during pregnancy, N (%)   0 (0.0)             1 (1.9)                          2 (1.6)                        0.662

BMI indicates body mass index.

There was no statistically significant difference between groups in all delivery outcomes (Table [2](#jah34232-tbl-0002){ref-type="table"}).

###### 

Delivery Outcomes

                                         Amlodipine (n=48)   Other Antihypertensives (n=54)   No Antihypertensives (n=129)   *P* Value
  -------------------------------------- ------------------- -------------------------------- ------------------------------ -----------
  Maternal outcomes                                                                                                          
  Superimposed preeclampsia, N (%)       15 (31.3)           14 (25.9)                        43 (33.3)                      0.615
  Gestational diabetes mellitus, N (%)   3 (6.3)             8 (14.8)                         24 (18.6)                      0.125
  Newborn outcomes                                                                                                           
  Gestational age, wks---mean (SD)       37.7 (2.14)         36.9 (3.43)                      37.1 (3.65)                    0.417
  Delivery weight, g---mean (SD)         2778.4 (619.54)     2520.1 (800.09)                  2536.0 (759.40)                0.123
  Preterm birth (\<37 wks), N (%)        10 (20.8)           12 (22.2)                        41 (31.8)                      0.221
  Low birth weight (\<2500 g), N (%)     12 (25.0)           24 (44.4)                        49 (38.0)                      0.116
  Apgar score                                                                                                                
  1 min, mean (SD)                       8.0 (0.99)          7.4 (1.97)                       7.6 (1.69)                     0.165
  5 min, mean (SD)                       8.9 (0.43)          8.5 (1.30)                       8.7 (1.22)                     0.203
  Birth defects, N (%)                   2 (4.2)             3 (5.6)                          6 (4.7)                        0.944

There was no statistically significant difference among the groups.

Morphologic abnormalities were observed in 11 of the 231 neonates: 2 of 48 neonates in Group A (4.2%; 95% CI, 0.51--14.25), 3 of 54 neonates in Group O (5.6%; 95% CI, 1.16--15.39), and 6 of 129 neonates in Group N (4.7%; 95% CI, 1.73--9.85) (Table [2](#jah34232-tbl-0002){ref-type="table"}: *P*=0.944). The odds ratio of the primary outcome comparing Group A and Group O was 0.74 (95% CI: 0.118--4.621) and Group A and Group N was 0.89 (95% CI: 0.174--4.575). Details of observed birth defects are summarized in Table [3](#jah34232-tbl-0003){ref-type="table"}. We were unable to identify any specific pattern of birth defects in this group.

###### 

Details of Cases of Morphologic Abnormalities

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case                Group        Birth Defects                                            Age at Delivery/Underlying Disease   Delivery Outcome   Superimposed Preeclampsia   Antihypertensive Agents    Other Drugs   
  ------------------- ------------ -------------------------------------------------------- ------------------------------------ ------------------ --------------------------- -------------------------- ------------- --------------------------------
  1                   A            PVS                                                      41 y.o.\                             35w4d\             −                           Prepregnancy to 4w6d       Am            12w0d to 28w0d: LDA
                                                                                            Essential hypertension               1872 g                                                                                  

  34w5d to 35w0d      Me                                                                                                                                                                                                 

  35w1d to delivery   Me, Nif                                                                                                                                                                                            

  2                   A            VSD                                                      36 y.o.\                             38w0d\             −                           Prepregnancy to 6w4d       Am            8w3d to 28w0d: LDA
                                                                                            Primary aldosteronism                3217 g                                                                                  

  6w5d to 8w0d        Hy                                                                                                                                                                                                 

  8w1d to delivery    Am                                                                                                                                                                                                 

  3                   O            Low‐lying conus medullaris/hypospadias/inguinal hernia   42 y.o.\                             29w1d\             \+                          Prepregnancy to 8w2d       La            12w6d to delivery: LDA
                                                                                            Essential hypertension               521 g                                                                                   

  9w4d to 12w0d       Me                                                                                                                                                                                                 

  12w1d to 12w5d      Me, La                                                                                                                                                                                             

  12w6d to 17w5d      Me, La, Am                                                                                                                                                                                         

  17w6d to delivery   Me, Am                                                                                                                                                                                             

  4                   O            VSD                                                      38 y.o.\                             25w6d\             −                           Prepregnancy to delivery   Nic, La       Prepregnancy to delivery: PSL\
                                                                                            Essential hypertension\              382 g                                                                                   3w to delivery: LDA
                                                                                            RA                                                                                                                           

  5                   O            Hypospadias                                              39 y.o.\                             39w4d\             \+                          8w4d to 30w2d              Me            None
                                                                                            Essential hypertension               2912 g                                                                                  

  30w3d to delivery   Me, Am                                                                                                                                                                                             

  6                   N            Hypospadias                                              33 y.o.\                             27w1d\             \+                          13w2d to 18w2d             Hy            12w0d to delivery: LDA
                                                                                            Essential hypertension               506 g                                                                                   

  18w2d to delivery   La                                                                                                                                                                                                 

  7                   N            Patent foramen ovale/low‐lying conus medullaris          40 y.o.\                             35w4d\             \+                          16w0d to 24w6d             Me            None
                                                                                            Essential hypertension               1351 g                                                                                  

  25w0d to delivery   Me, Nif                                                                                                                                                                                            

  8                   N            Low anorectal anomaly/low‐lying conus medullaris         42 y.o.\                             26w0d\             \+                          21w0d to 21w1d             Me            None
                                                                                            Essential hypertension               379 g                                                                                   

  21w2d to delivery   Me, Am                                                                                                                                                                                             

  9                   N            Low‐lying conus medullaris                               37 y.o.\                             34w3d\             −                           16w4d to 28w5d             Me            None
                                                                                            Essential hypertension               2108 g                                                                                  

  28w6d to delivery   Me, Am                                                                                                                                                                                             

  10                  N            Potter syndrome                                          40 y.o.\                             33w6d\             −                           None                                     None
                                                                                            Essential hypertension               1836 g                                                                                  

  11                  N            Colpocephaly                                             32 y.o.\                             40w4d\             −                           None                                     None
                                                                                            Essential hypertension               3396 g                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A indicates amlodipine group; Am, amlodipine; Hy, hydralazine; La, labetalol; LDA, low‐dose aspirin; Me, methyldopa; N, No antihypertensive group; Nic, nicardipine; Nif, nifedipine; O, Other antihypertensive group; PSL, prednisolone; PVS, pulmonary valve stenosis; RA, rheumatoid arthritis; VSD, ventricular septal defect; y.o., years old.

We have calculated total dose to quantify the exposure ([Table S2](#jah34232-sup-0001){ref-type="supplementary-material"}). Total dose was obtained by amlodipine daily dose times the total number of days of amlodipine uses during the first trimester. The average of total dose±SD and the total number of days±SD of amlodipine use for all cases were 363.6±257.9 mg and 65.0±25.9 days. Those of cases with birth defects were 175 mg, 35 days (Case 1 in Table [3](#jah34232-tbl-0003){ref-type="table"}) and 740 mg, 74 days (Case 2 in Table [3](#jah34232-tbl-0003){ref-type="table"}).

Our study cohort included 10 women with diabetes mellitus, a known risk factor for congenital anomalies: 3 in group A, 1 in group O, and 6 in group N, although there were no birth defects among them. We performed a subgroup analysis after excluding these subjects, but group differences remained not statistically significant (*P*=0.960): morphologic abnormalities were observed in 11 of the 221 neonates: 2 of 45 neonates in Group A (4.4%; 95% CI, 0.54--15.15), 3 of 53 neonates in Group O (5.7%; 95% CI, 1.18--15.66), and 6 of 123 neonates in Group N (4.9%; 95% CI, 1.81--10.32) ([Table S3](#jah34232-sup-0001){ref-type="supplementary-material"}). In this subgroup analysis, the odds ratio of the primary outcome comparing Group A and Group O was 0.78 (95% CI: 0.124--4.857) and Group A and Group N was 0.91 (95% CI: 0.176--4.666).

A pair of twins who were excluded from the final analysis were exposed to amlodipine in early pregnancy. We listed delivery outcomes including the twins in Group A in [Table S4](#jah34232-sup-0001){ref-type="supplementary-material"}.

Discussion {#jah34232-sec-0019}
==========

In this study, the rate of chronic hypertension was 0.9% and the rate of preeclampsia and gestational hypertension was 1.8%. These rates are lower than those expected from previous data in Japan, which are 0.6% to 3.5% (0.6%; age 30--34, 1.2%; age 35--39, 2.0%; age 40--44, 3.5%; age ≥45)[10](#jah34232-bib-0010){ref-type="ref"} for chronic hypertension, 2.3% for preeclampsia, and 2.3% for gestational hypertension.[11](#jah34232-bib-0011){ref-type="ref"}

Amlodipine Use and Morphologic Abnormalities {#jah34232-sec-0020}
--------------------------------------------

In this study, fetal morphologic abnormalities associated with exposure to amlodipine in the first trimester were investigated in pregnant women with chronic hypertension in Japan. Previous studies reported a total of 41 cases in which amlodipine was administered during the first trimester of pregnancy, and our dataset has added an additional 48 amlodipine‐exposed cases in the literature. In our study, morphologic abnormalities were observed in 2 neonates in Group A (4.2%). In this group, 26 women were exposed to only amlodipine in the first trimester. Our findings indicate that the point estimates of the odds of major malformations are not significantly different among the groups. However, the 95% CI was wide because of the small sample size. While our exploratory data are reassuring, further research effort is clearly needed.

Use of Antihypertensives and Morphologic Abnormalities {#jah34232-sec-0021}
------------------------------------------------------

The use of antihypertensives in the first trimester has generally been found not to increase the risk of morphologic abnormalities in offspring,[3](#jah34232-bib-0003){ref-type="ref"}, [4](#jah34232-bib-0004){ref-type="ref"}, [12](#jah34232-bib-0012){ref-type="ref"}, [13](#jah34232-bib-0013){ref-type="ref"}, [14](#jah34232-bib-0014){ref-type="ref"}, [15](#jah34232-bib-0015){ref-type="ref"}, [16](#jah34232-bib-0016){ref-type="ref"} although studies exist showing potential associations with birth defects such as heart malformation,[6](#jah34232-bib-0006){ref-type="ref"}, [17](#jah34232-bib-0017){ref-type="ref"}, [18](#jah34232-bib-0018){ref-type="ref"}, [19](#jah34232-bib-0019){ref-type="ref"} hypospadias,[20](#jah34232-bib-0020){ref-type="ref"}, [21](#jah34232-bib-0021){ref-type="ref"} and central nervous system malformation.[17](#jah34232-bib-0017){ref-type="ref"} In our study, abnormalities were observed in 5 of 102 (4.9%) neonates whose mothers used antihypertensives in the first trimester (Group A+Group O) and 6 of 129 (4.7%) whose mothers did not use antihypertensives (Group N). Among the 5 offspring in the antihypertensive groups (Group A+Group O), 3 had heart malformations, and 2 had hypospadias. There was no increase in the risk of morphologic abnormalities in the exposed groups, compared with the group that did not take antihypertensives (Group N) (*P*=0.929), although the relatively frequent occurrence of heart malformations and hypospadias was consistent with previous reports.[6](#jah34232-bib-0006){ref-type="ref"}, [17](#jah34232-bib-0017){ref-type="ref"}, [18](#jah34232-bib-0018){ref-type="ref"}, [19](#jah34232-bib-0019){ref-type="ref"}, [20](#jah34232-bib-0020){ref-type="ref"}, [21](#jah34232-bib-0021){ref-type="ref"} In the present study, the women whose offspring had heart malformations or hypospadias did not use any nonantihypertensive drugs that are associated with heart malformations[22](#jah34232-bib-0022){ref-type="ref"} or hypospadias.[23](#jah34232-bib-0023){ref-type="ref"}

Maternal Hypertension and Morphologic Abnormalities {#jah34232-sec-0022}
---------------------------------------------------

As Shepard proposed,[24](#jah34232-bib-0024){ref-type="ref"} one of the essential criteria for a human teratogen is a specific phenotype(s) of the adverse effects. An association between maternal hypertension and specific birth defects was recently reported.[6](#jah34232-bib-0006){ref-type="ref"}, [19](#jah34232-bib-0019){ref-type="ref"}, [21](#jah34232-bib-0021){ref-type="ref"}, [25](#jah34232-bib-0025){ref-type="ref"}, [26](#jah34232-bib-0026){ref-type="ref"} Anomalies in the kidney, limbs, lips, and palate were frequently observed in the offspring of women with chronic hypertension.[7](#jah34232-bib-0007){ref-type="ref"} Maternal hypertension was also found to be associated with heart malformation,[6](#jah34232-bib-0006){ref-type="ref"}, [19](#jah34232-bib-0019){ref-type="ref"}, [21](#jah34232-bib-0021){ref-type="ref"}, [25](#jah34232-bib-0025){ref-type="ref"}, [26](#jah34232-bib-0026){ref-type="ref"}, [27](#jah34232-bib-0027){ref-type="ref"} hypospadias,[28](#jah34232-bib-0028){ref-type="ref"} and esophageal atresia or stenosis.[29](#jah34232-bib-0029){ref-type="ref"} In our study, consistent with the previous reports, the following abnormalities (including overlap) occurred in the offspring of women with chronic hypertension: heart malformation in 3 cases, hypospadias in 3, central nervous system abnormalities in 5, and renal abnormality (Potter syndrome) in 1. Possible teratogenicity of maternal hypertension itself cannot be ruled out or confirmed from the current study framework, mainly because of the absence of nonhypertensive control.

Importantly, 5 of 11 women in this study whose offspring showed morphologic abnormalities had superimposed preeclampsia (2 women in Group O and 3 women in Group N). Of these 5 women, 3 demonstrated hypospadias and 3 exhibited low‐lying conus medullaris. van Gelder et al reported a high risk of ventricular septal defect and atrial septal defect in chronic hypertension women who developed superimposed preeclampsia (antihypertensives were not used).[21](#jah34232-bib-0021){ref-type="ref"} Maternal hypertension is speculated to directly affect fetal growth via vascular disruption or teratogenic mechanisms.[30](#jah34232-bib-0030){ref-type="ref"} Physiological changes in early pregnancy that progress to preeclampsia or gestational hypertension in late pregnancy are also speculated to be associated with morphologic abnormalities in some cases.[21](#jah34232-bib-0021){ref-type="ref"} Whether these observations reflect the teratogenic nature of maternal hypertension requires further studies.

Limitations {#jah34232-sec-0023}
-----------

We conducted a simulation about the unmeasured confounding factors that could have effects on birth defects in the comparison of Group A and Group N as a sensitivity analysis. We set a confounder‐birth defects odds ratio equal to 0.1, and the prevalence of confounding factors among Group N was equal to 0.05. We estimated the odds ratio of group‐birth defects depending on the prevalence of confounding factors among Group A. Within the condition of our sample size, when the prevalence of confounding factors among Group A was 0.95, the lower limit of 95% CI exceeds 1 (Figure [2](#jah34232-fig-0002){ref-type="fig"}). These results indicate that we cannot draw a conclusion regarding the difference in birth defects in this study. Because of this limitation, the effects of confounding maternal background factors such as age, body mass index, alcohol, smoking, underlying diabetes mellitus, and underlying congenital heart disease could not be examined.

![Unmeasured confounder‐birth defects odds ratio. The 95% CI was estimated by the range of 2.5 and 97.5 percentile points of exp (log \[odds ratio\]+error), which was calculated by Monte Carlo simulations. The error term was randomly sampled from the Normal distribution with mean 0 and the SD, which was substituted by the SE of unadjusted log odds ratio.](JAH3-8-e012093-g002){#jah34232-fig-0002}
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